Bausch Health Companies | VRX - Assets


Bausch Health Companies reported $24.79B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Amgen USD 95.64B 3.14B Jun/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Aurora Cannabis CAD 601.09M 174.2M Mar/2026
Bausch Health Companies USD 24.79B 296M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Danaher USD 92.37B 8.82B Jun/2026
Drreddys Laboratories INR 579.35B 573.08B Mar/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Phibro Animal Health USD 1.45B 39.56M Mar/2026
Prestige Brands USD 4.57B 1.07B Jun/2026
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026
Zoetis USD 15.15B 313M Mar/2026